Quote this publication Share Print

GLIVEC

-
Opinions on drugs - Posted on May 20 2008

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use for “the treatment of myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements".

-


Actual benefit

Important

The actual benefit of Glivec is substantial.


Improvement in actual benefit

III (modéré)

GLIVEC provides a moderate improvement in actual benefit (IAB III) in terms of efficacy as compared with the usual management of myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangement.


Contact Us

Évaluation des médicaments